http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111481674-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db5f68c6eed071c0bbe13aa7b988799e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 |
| filingDate | 2020-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87c689d63f4b69939d45f2e8f5ba6047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8655919410f969ae86445357f33300fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_446e5d4f171bfbb7a906cb87cb63300b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c7920b237d8b624ae0dfb6230c9d781 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6533a0a37345741a31968627e94dd484 |
| publicationDate | 2020-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111481674-A |
| titleOfInvention | Application of inhibitors of TRPA1 in the preparation of multiple sclerosis drugs |
| abstract | The invention discloses the application of the inhibitor of TRPA1 in the preparation of a medicine for treating multiple sclerosis. The TRPAl inhibitor can be used to prepare a drug for treating multiple sclerosis caused by lysophosphatidylcholine (LPC). The present invention explores the expression of TRPA1 on OLN-93 oligodendrocytes and the involvement of TRPA1 in LPC-induced oxidative stress and cell damage by establishing a model based on OLN-93 oligodendrocyte oxidative stress and cytotoxicity. The results showed that the inhibitor of TRPA1 can significantly inhibit the influx of calcium ions in the cytoplasm and mitochondria, significantly reduce the production of mitochondrial reactive oxygen species, significantly inhibit the decrease of mitochondrial membrane potential, significantly inhibit the production of NO, significantly inhibit the increase of superoxide, and effectively inhibit the decrease of mitochondrial membrane potential. Increased dendritic cytotoxicity. Therefore, TRPA1 inhibitors can be used to treat demyelinating diseases such as multiple sclerosis caused by LPC. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114903995-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114903995-B |
| priorityDate | 2020-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.